Why femtech adoption in Southeast Asia stops at the clinic door

Southeast Asia's femtech market presents an intriguing paradox – while a majority of women in the region already use women's health products and services, adoption rates stop at the clinic door. A recent study by FemTech Association Asia and Milieu Insight across six markets reveals that awareness of the term "femtech" is low, but usage is high.

In the Philippines and Indonesia, 65% and 55% of women respectively use femtech tools, and 57% and 69% of non-users plan to start within six months. The barrier appears to lie not in demand or education, but in supply – whether the current offerings are compelling enough to convert existing intent.

The majority of femtech adoption is concentrated at the consumer layer, with usage clustering around menstrual products and cycle-tracking apps. These products allow women to research, buy, or download them without involving a clinician, addressing practical concerns of ease, convenience, and cost. However, categories that require clinical interaction, like screening or specialist consults, show far less adoption. Women's decision-making is driven by convenience and cost, not by the clinical nature of the service.

Interestingly, women increasingly source health information online rather than from clinicians, with social media being a leading channel, especially for issues like menopause. This pattern indicates that the information and tracking layers have fully digitized, but the step that converts that information into care has not. While a tracker can inform a woman about irregularities in her cycle, it typically cannot connect her to the necessary clinical intervention, such as an OB-GYN or PCOS screening.

Discretion is a significant constraint in this process. Across the six markets, roughly half of women express concern about judgment or shame when discussing their health openly. This privacy concern often leads women to start their health journey privately, on their devices, rather than in a clinical setting. For femtech products to successfully convert this intent, they must preserve privacy throughout the entire journey, from the moment of concern to the point of screening or consultation. Products that maintain discretion will likely have a higher conversion rate.

In summary, the demand for femtech in Southeast Asia is evident and increasing, but the market is constrained by supply – the current offerings lack the necessary connective tissue to move women through the healthcare system efficiently and affordably. For investors and builders in this space, the focus should shift from merely adding more measurement tools to creating a seamless experience that takes an engaged user from tracking to screening to treatment, all while maintaining consumer-grade convenience, cost, and discretion.